See where the smart money is betting on ageing
$8.49 billion went into ageing last year. The same handful of investors sat behind most of it. This report, delivered to your inbox, shows you who they are, what they're funding and where the field goes next, all before the rest of the market catches up.
Featuring insights from:
What you walk away with
Twenty minutes from now, you'll be reading the sector the way the insiders do
See hidden patterns
The same handful of investors are funding almost everything. See the connections and longevity stops feeling chaotic. The next decade becomes legible.
Read the field instantly
Cellular reprogramming. Senolytics. AI-driven discovery. Cellular repair. Preventative medicine. Serious capital is moving through five ideas.
Spot the strategies
GV is betting on data platforms. ARCH is funding deep-science moonshots. Khosla and a16z are building consumer brands. Three philosophies chase one prize.
Introducing The Unfiltered Longevity 100
Inside your report: The investors, founders, scientists and influencers who decide where longevity goes next. Ranked.
The first ever Unfiltered Longevity 100 ranks the people most actively shaping where longevity goes next. Four categories: investors, founders, scientists and influencers. Every person scored across five weighted criteria, from capital deployed to scientific credibility to category creation. The result is a map of who really runs the field in 2026. Here's a preview of the top five.
05.
Demis Hassabis
CEO, Isomorphic Labs · 89.5
Not a longevity figure in the traditional sense. The reason the next decade of longevity drugs will exist.
04.
Bob Nelsen
Co-founder, ARCH Venture Partners · 89.5
The reason Altos Labs exists. Anchored the largest biotech round ever raised.
03.
Vinod Khosla
Founder, Khosla Ventures · 90.5
Most longevity investors place one big bet. Khosla has placed ten.
02.
Mehmood Khan
CEO, Hevolution Foundation · 91.0
Writes the cheques behind the largest philanthropic longevity pool on earth. Up to a billion dollars a year.
01.
The advantage
of seeing it first
Most longevity coverage stops at the headline. This goes deeper; to the capital, the science and the strategies that decide what the headlines actually mean. It's the fastest way to read the sector the way the people funding it do.
Six things you'll know that almost nobody else does
Each one represents something most of the longevity conversation hasn't caught up to yet
$3 billion before a single drug
Altos Labs raised the largest biotech round in history with no trial, no product and no published result. The money is the easy part of the story. What the backers were actually buying is the part that explains the future of longevity.
Fewer deals, bigger cheques
Longevity funding crashed 60% in 2023 then came back bigger and more focused in 2024. The same money is moving into fewer companies at higher conviction. Knowing which firms are writing the bigger cheques tells you where the field is consolidating.
The $367 trillion prize
One extra year of healthy global lifespan adds $38 trillion to the world economy. Ten years adds $367 trillion. This is the number that explains why the smartest capital in technology is not funding a new app. It's funding a new theory of medicine.
Resetting the biological clock
$1.94 billion is now chasing the idea that ageing can be reversed at the cellular level. Not just slowed but reversed. Discover the key companies, the scientists, the investors and what each of them think they've found.
GV vs ARCH vs Khosla
Three of the most powerful investors are attacking the same problem from three completely different angles. The disagreement is the story. Once you see what each one believes, every longevity portfolio starts to make sense.
From data to drugs
The last decade of longevity built tools to measure ageing. The next decade is building drugs to change it. The transition is happening now. The report shows you which companies, which capital and which technologies are leading it.
See the structure behind the boom
Longevity stops feeling chaotic the moment you can see the structure behind it. Five bets. Three strategies. One small group of investors. A handful of companies leading the charge. This report gets you there in twenty minutes and gives you something most people in the sector don't have: a working map of where the next decade goes.
Frequently Asked Questions
Who is this report for?
This report is designed for investors, operators and anyone seriously interested in longevity, health innovation and the future of preventative medicine.
Is this a scientific paper or an industry report?
Neither. It's an investment intelligence brief. Built from primary research and structured to reveal the patterns that decide where the money goes next.
How long is the report?
53 pages, designed to be navigated in sections rather than read end-to-end. Twenty minutes will give you the full strategic picture. Two hours will give you every detail.
What makes this different from other longevity content?
Most longevity coverage focuses on individual breakthroughs. This focuses on the system. Once you see how the capital, the science and the strategy connect, the next decade of longevity stops being unpredictable.
Who created this
Unfiltered is a media platform covering the science, capital and ideas reshaping how we live, work and age. We interview the people building the future; investors, scientists and founders and turn those conversations into insights and analysis you won't get anywhere else.
This report is the first in a series of intelligence briefs covering health, performance and human potential. The next ones land soon. To get them first, sign up now.
If you want to understand longevity, follow the money
Conviction is building in a small number of places. This report shows you where. Read it before the market catches up.
Takes 10 seconds. No spam, no upsell.
© 2026 Unfiltered Media Ltd
All rights reserved.